Quantcast

Latest Anthracyclines Stories

2010-09-21 06:30:00

COLUMBIA, Md., Sept. 21 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW...

2010-09-02 13:15:00

COLUMBIA, Md., Sept. 2 /PRNewswire-FirstCall/ --Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer". This funding will support the Company's efforts to develop its proprietary heat-activated liposomal technology in...

2010-09-01 07:00:00

PRINCETON, N.J., Sept. 1 /PRNewswire/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing. Proceeds will support completion of ongoing clinical trials and activities related to advancing the company's lead investigational product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection as a...

2010-08-03 06:30:00

COLUMBIA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular...

2010-06-21 12:38:00

PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH). The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. "We are pleased that work with this research program has led to its expansion and excited that a global biopharmaceutical company of Cephalon's stature is...

2010-06-14 07:00:00

PRINCETON, N.J., June 14 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen. The results were presented at the 15th Congress of the European...

2010-06-14 06:30:00

COLUMBIA, Md., June 14 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology (ASTRO) Annual Meeting. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in...

2010-06-07 06:30:00

Encouraging trend observed in overall survival QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer. The presentation was made by Prof. Gunter Emons, Chairman, Department of Obstetrics & Gynaecology...

2010-05-21 07:35:00

QUEBEC CITY, May 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that data on two of its lead anticancer compounds, perifosine and AEZS-108, will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4 through 8, 2010 at McCormick Place in Chicago. Two posters on perifosine, Aeterna...

2010-05-18 00:30:00

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL). While CHOP-R is considered the standard of...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.